A new study published in PLoS ONE showed that one in four patients with hepatitis C virus infection who apply for treatment of the infection is initially denied.
“Delay in access may further challenge our ability to cure hepatitis C in this country,” Joseph K. Lim, MD, associate
professor of medicine and director of the Yale Viral Hepatitis Program
at Yale University, said in a press release. “Some patients are told
they must wait until they have advanced liver disease before they can
undergo potentially curative treatment. We hope these data may help
inform national policy discussions on promoting more rational,
patient-centered approaches to HCV treatment access.”
“This is the first study to our knowledge assessing real-world access to
interferon-free [direct-acting antiviral] regimens in established
cohorts of patients with chronic HCV seeking antiviral therapy,” the
researchers wrote. “These results contribute to the limited data
available addressing proportion of patients successfully obtaining drug
authorization through public and private insurance carriers, time to
approval, and predictors for approval. … Further studies are warranted
to investigate the impact of evolving drug authorization policies by
Medicare/Medicaid and private payers on access to curative HCV therapies
such as [sofosbuvir and ledipasvir].” – by Melinda Stevens.
Do A, et al. PLoS One. 2015;doi:10.1371/journal.pone.0135645.
Labels: access to treatment, denied treatment